<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neurol</journal-id><journal-id journal-id-type="iso-abbrev">J Neurol</journal-id><journal-title-group><journal-title>Journal of Neurology</journal-title></journal-title-group><issn pub-type="ppub">0340-5354</issn><issn pub-type="epub">1432-1459</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38972019</article-id><article-id pub-id-type="pmc">PMC11377679</article-id>
<article-id pub-id-type="publisher-id">12544</article-id><article-id pub-id-type="doi">10.1007/s00415-024-12544-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Communication</subject></subj-group></article-categories><title-group><article-title>Muscle MRI as a biomarker of disease activity and progression in myotonic dystrophy type 1: a longitudinal study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8813-2272</contrib-id><name><surname>Fionda</surname><given-names>Laura</given-names></name><address><email>laura.fionda@uniroma1.it</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Leonardi</surname><given-names>Luca</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tufano</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lauletta</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Morino</surname><given-names>Stefania</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Merlonghi</surname><given-names>Gioia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Costanzo</surname><given-names>Rocco</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rossini</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Forcina</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Marando</surname><given-names>Demetrio</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sarzi Amad&#x000e8;</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bucci</surname><given-names>Elisabetta</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Salvetti</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Antonini</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Garibaldi</surname><given-names>Matteo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/032298f51</institution-id><institution-id institution-id-type="GRID">grid.415230.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 123X</institution-id><institution>Neuromuscular and Rare Disease Centre, </institution><institution>Neurology Unit, Sant&#x02019;Andrea Hospital, </institution></institution-wrap>Rome, Italy </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02be6w209</institution-id><institution-id institution-id-type="GRID">grid.7841.a</institution-id><institution>Department of Neuroscience, </institution><institution>Mental Health and Sensory Organs (NESMOS), SAPIENZA University of Rome, </institution></institution-wrap>Rome, Italy </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2024</year></pub-date><volume>271</volume><issue>9</issue><fpage>5864</fpage><lpage>5874</lpage><history><date date-type="received"><day>10</day><month>3</month><year>2024</year></date><date date-type="rev-recd"><day>22</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>6</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction</title><p id="Par1">Myotonic dystrophy type 1 (DM1) is an autosomal dominant disease characterized by myotonia and progressive muscular weakness and atrophy. The aim of this study was to investigate the usefulness of longitudinal muscle MRI in detecting disease activity and progression in DM1, and to better characterize muscle edema, fat replacement and atrophy overtime.</p></sec><sec><title>Materials and methods</title><p id="Par2">This is a prospective, observational, longitudinal study including 25 DM1 patients that performed at least two muscle MRIs. Demographic and genetic characteristics were recorded. Muscular Impairment Rating Scale (MIRS) and MRC score were performed within 3&#x000a0;months from MRIs at baseline (BL) and at follow-up (FU). We analysed 32 muscles of lower body (LB) and 17 muscles of upper body (UB) by T1 and STIR sequences. T1-, STIR- and atrophy scores and their variations were evaluated. Correlations between MRIs&#x02019; scores and demographic, clinical and genetic characteristics were analysed.</p></sec><sec><title>Results</title><p id="Par3">Eighty (80%) of patients showed fat replacement progression at FU. The median T1 score progression (&#x00394;T1-score) was 1.3% per year in LB and 0.5% per year in UB. The rate of fat replacement progression was not homogenous, stratifying patients from non-progressors to fast progressors (&#x0003e;&#x02009;3% &#x00394;T1-score per year). Half of the STIR-positive muscles at BL showed T1-score progression at FU. Two patients with normal MRI at baseline only showed STIR-positive muscle at FU, marking the disease activity onset. STIR positivity at baseline correlated with fat replacement progression (&#x00394;T1-score; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) and clinical worsening at FU (&#x00394;MRC-score; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001). Sixty-five (65%) of patients showed STIR- and fat replacement-independent muscle atrophy progression, more evident in UB.</p></sec><sec><title>Conclusions</title><p id="Par4">Muscle MRI represents a sensitive biomarker of disease activity, severity, and progression in DM1. STIR alterations precede fat replacement and identify patients with a higher risk of disease progression, while T1-sequences reveal atrophy and fat replacement progression before clinical worsening.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Myotonic dystrophy type 1</kwd><kwd>Muscle MRI</kwd><kwd>Longitudinal study</kwd><kwd>Biomarkers</kwd></kwd-group><funding-group><award-group><funding-source><institution>Universit&#x000e0; degli Studi di Roma La Sapienza</institution></funding-source></award-group><open-access><p>Open access funding provided by Universit&#x000e0; degli Studi di Roma La Sapienza within the CRUI-CARE Agreement.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Myotonic dystrophy type 1 (DM1) is the most common muscular dystrophies in adults caused by a CTG-trinucleotide expansion in the 3&#x000b4; untranslated region (UTR) of the <italic>dystrophia myotonica protein kinase</italic> (<italic>DMPK</italic>) gene [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par6">DM1 is progressive multisystemic disease with skeletal and cardiac muscles primarily affected, causing myotonia and progressive muscular weakness and atrophy [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par7">Muscle involvement in DM1 can be easily detected by muscle magnetic resonance imaging (MRI), which represents the gold standard technique for imaging study in muscle diseases [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Its usefulness in recognizing the pattern and severity of fat replacement, muscle atrophy and extracellular edema by T1- and T2-Short-tau-inversion-recovery (STIR)-sequences is well known, as well as its association with disease activity and progression in several muscle diseases [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. We recently reported cross-sectional data from 134 DM1 patients showing that (1) fat replacement, detected by T1-sequences, correlates with clinical impairment and subclinical muscle involvement can also be detected in the milder spectrum of disease; (2) positive STIR-signal, detected in about 80% of patients, represents a marker of disease activity and seems to precede fat replacement; (3) muscle atrophy and &#x0201c;marbled&#x0201d; appearance, suggesting a premature senescence of muscle tissue, represent additional mechanisms for muscle wasting and weakness [<xref ref-type="bibr" rid="CR9">9</xref>]. Only few studies investigated quantitative muscle MRI (qMRI) in DM1 and only one study reported longitudinal MRI data for short periods of FU observation [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par8">In the gene-therapy era [<xref ref-type="bibr" rid="CR12">12</xref>], objective evaluation of natural history of progressive diseases and their correlations with clinical evolution overtime are warranted. Longitudinal studies of muscle MRI represent a potential biomarker in monitoring the natural history of disease progression and better understand the pathophysiological mechanism of disease in DM1, but it could also represent a sensitive outcome measure of response to treatment for forthcoming clinical trials, as it occurs in other myopathies [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par9">In this framework, we aimed to investigate the value of longitudinal muscle MRI study as a biomarker and prognostic factor of disease activity and progression in DM1.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Patients</title><p id="Par10">This is a prospective, observational, longitudinal study including DM1 patients belonging to Sant&#x02019;Andrea Hospital of Sapienza University of Rome. It was carried out with previous patients&#x02019; informed consent and in compliance with ethical standards of local ethical committees, the Helsinki Declaration, and the Good Clinical Practice.</p><p id="Par11">All patients had genetically confirmed DM1 and performed two MRI studies including STIR and T1 sequences between July 1st, 2016, and January 1st, 2023, for routine diagnostic and clinical purposes.</p><p id="Par12">Demographic and clinical data were collected for each patient.</p><p id="Par13">Molecular diagnosis of DM1 was performed on DNA obtained from peripheral leukocytes at the moment of clinical diagnosis. Patients were grouped into three expansion classes according to CTG expansion range: E1 (CTG 50&#x02013;150), E2 (CTG 151&#x02013;1000) and E3 (CTG&#x02009;&#x0003e;&#x02009;1000).</p><p id="Par14">Patients were also stratified into five clinical forms based on first disease-related symptoms onset: (I) congenital (at birth), (II) infantile (1&#x02013;10&#x000a0;years), (III) juvenile (11&#x02013;20&#x000a0;years), (IV) adult (21&#x02013;40&#x000a0;years) and (V) late onset (&#x0003e;&#x02009;40&#x000a0;years).</p><p id="Par15">All patients received a complete neurological examination, including an extensive manual muscle test scored by the Medical Research Council (MRC) scale evaluating arm abductors, forearm flexors and extensors, finger extensors, hip flexors, tight flexors and extensors, foot flexors and extensors bilaterally (MRC-100), as part of their clinical follow&#x02010;up, and Muscular Impairment Rating Scale (MIRS) [<xref ref-type="bibr" rid="CR16">16</xref>] was calculated at each visit scheduled for clinical purposes. For this study, we programmed a clinical evaluation within 3&#x000a0;months from each muscle MRI assessment.</p></sec><sec id="Sec4"><title>Muscle MRI studies</title><p id="Par16">All muscle MRIs were obtained using a 1.5-T MRI following previously described protocols [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] in accordance with the international consensus recommendations [<xref ref-type="bibr" rid="CR19">19</xref>]. A total of 32 muscles of lower body (LB) and 17 muscles of upper body (UB) from each side were analysed. LB included lower limbs, pelvic girdle, abdominal muscles and lumbar paraspinal muscles whereas UB included head, neck, scapular girdle and chest muscles. T1 Turbo spin echo (T1-TSE) and T2-Short tau inversion recovery (T2-STIR) sequences were obtained in each study with axial, coronal and sagittal planes. The following muscles were grouped and evaluated together because of the difficulty in evaluating them independently in most cases: <italic>obliquus abdominis externus/internus&#x02010;transversus abdominis; obturatorius externus/internus; extensor digitorum/hallucis longus; peroneus longus/brevis; tibialis posterior/flexor digitorum longus; pterygoideus internus/externus; cervical paraspinal muscles; thoracic paraspinal muscles; teres major/minor</italic>.</p><p id="Par17">The duration of the MRI exam was approximately 50&#x000a0;min.</p><p id="Par18">Axial T1&#x000a0;sequence (TR/TE of 400/13&#x000a0;ms, thickness/gap 4&#x000a0;mm/0, 4&#x000a0;mm, field of view [FOV] 370&#x000a0;mm) was performed by two contiguous stacks to obtain an anatomic coverage from the skull base to the ankles. STIR axial images (TR/TE/TI 3000/35/160&#x000a0;ms) were also acquired with the same anatomical coverage of T1 sequences. For the upper body, T1&#x000a0;sequences also included coronal (TR/TE of 450/13&#x000a0;ms, thickness/gap 3.5&#x000a0;mm/0.35&#x000a0;mm, FOV 400&#x000a0;mm) and sagittal (TR/TE of 630/13&#x000a0;ms, thickness/gap 5&#x000a0;mm/0.5&#x000a0;mm, FOV 400&#x000a0;mm) acquisitions to better evaluate the neck and thoracic muscles. Three coronal stacks were obtained to assess anterior and posterior thoracic muscles and neck muscles. Slices were oriented along (I) the axis of the pectoralis major muscle for anterior thoracic muscles, (II) parallel to the dorsal kyphosis for posterior thoracic muscles and (III) the major axis of the neck for neck muscles. Sagittal stack was oriented to cover from one shoulder to the other.</p><p id="Par19">Fat replacement was assessed for each muscle, evaluated throughout the whole muscle bulk, on T1 sequences using a six-point scale (0&#x02013;5) according to modified Mercuri classification [<xref ref-type="bibr" rid="CR20">20</xref>] as previously reported, while edema/inflammation on STIR sequences using a two-point scale (0: negative, 1: positive).</p><p id="Par20">The degree of muscle atrophy was evaluated by a semiquantitative five-point scale in lower body considering posterior, medial and anterior compartments of the thigh, and anterior and posterior compartments of the leg [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. In the upper body muscle atrophy was assessed for four isolated muscles: <italic>sternocleidomastoideus</italic>, <italic>trapezius</italic>, <italic>pectoralis minor</italic> and <italic>major</italic> [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par21">We obtained the overall percentage of STIR positivity as a fraction of STIR-positive muscles over the total number of muscles evaluated (STIR%&#x02009;=&#x02009;total n&#x000b0;STIR-positive muscles/total muscles evaluated*100). STIR% was also calculated separately in UB and LB (STIR%UB and STIR%LB).</p><p id="Par22">The overall burden of fat replacement was obtained as a sum of T1 score of each muscle per patient (T1-score) ranging between 0 (no fat replacement at all) and 485 (the value corresponding to the max T1-score&#x02009;=&#x02009;5 for all muscles: 97&#x02009;&#x000d7;&#x02009;5&#x02009;=&#x02009;485). We also calculated the T1-score for UB and LB independently (T1-UB score and T1-LB score, respectively). We obtained the percentage of T1-score as a fraction of the sum of T1 scores of all muscles over the value of max T1-score for all muscles per patient (T1%&#x02009;=&#x02009;sum of T1-score of all muscles/sum of max T1-score in all muscles*100).</p><p id="Par23">For longitudinal evaluation of MRI changes, we evaluated the variation of STIR% and T1-score over time (&#x00394;STIR% and &#x00394;T1% scores respectively), between the first and last MRI available for each patient. We also analysed &#x00394;STIR% and &#x00394;T1% scores for UB and LB independently.</p><p id="Par24">T1 and STIR sequences of head, scapular girdle and trunk were not available for one patient at baseline and for one patient at follow-up.</p><p id="Par25">Two independent Neurologists with experience in MRI analysis (MG, LF) blinded to demographic and clinical data analysed all MRIs. In muscles with different T1 and STIR scoring, observers reviewed the muscles together to agree the final score.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par26">Continuous variables were expressed as mean, range, and inter quartile range (IQR).</p><p id="Par27">We identified that none of the variables analysed was normally distributed using Kolmogorov&#x02013;Smirnov and, therefore, we used non-parametric statistical studies. Mann&#x02013;Whitney <italic>U</italic> test was used to identify whether differences observed between two groups were significant. Wilcoxon signed rank test was used to determine whether differences observed in continuous variables at two time points (BL and FU) were statistically significant (e.g., T1-LB score at BL and at FU). When multiple comparisons were performed, we applied a post hoc Bonferroni correction. Chi-square test was used for comparison of categorical variables. Spearman rank-order test was run to assess if correlations between variables were statistically significant. Correlation coefficients are expressed as <italic>r</italic> and considered strong correlation if higher than 0.8 and good if higher than 0.6. Two-sided <italic>p</italic> values were calculated for all analyses; values of&#x02009;&#x0003c;&#x02009;0.05 were considered significant. All these analyses, as well as the graphics development, were performed using JASP Statistics 0.16 (IBM, Armonk, New York, USA) and GraphPad Prism 8.2.1.</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Patients</title><p id="Par28">Twenty-five patients (13 males, 12 females), aged between 18 and 81&#x000a0;years (mean 41, SD&#x02009;&#x000b1;&#x02009;16), were included in the study.</p><p id="Par29">Median age at disease onset was 27 (IQR 16&#x02013;43, range 0&#x02013;81).</p><p id="Par30">CTG average expansion range was 50&#x02013;1250 (median 475, IQR 308&#x02013;575). Four patients were in E1 expansion class, 19 in E2 and 2 patients in E3.</p><p id="Par31">Median disease duration at first MRI study was 9&#x000a0;years (IQR 3.5&#x02013;16.5, range 0&#x02013;43), with three patients still asymptomatic, while at the second MRI was 11&#x000a0;years (IQR 6.5&#x02013;20, range 2&#x02013;45). Median follow-up duration was 37&#x000a0;months (IQR 32&#x02013;47, range 21&#x02013;53) between the first and the second MRI.</p><p id="Par32">MIRS evaluation at BL showed a mean value of 2.84 (SD&#x02009;&#x000b1;&#x02009;0.75), while at FU it was 3.04 (SD&#x02009;&#x000b1;&#x02009;0.89). Median MIRS was 3 at baseline (range 1&#x02013;4, IQR 2&#x02013;3) and at follow-up (range 1&#x02013;5, IQR 2.5&#x02013;4). At first MRI, 1 patient had MIRS 1, 6 patients had MIRS 2, 14 patients had MIRS 3, 4 patients had MIRS 4. At follow-up, MIRS progression was observed in 5 patients (one MIRS 2 to 3; three MIRS 3 to 4; one MIRS 4 to 5).</p><p id="Par33">Overall median MRC at BL was 93,3 (range 76.5&#x02013;100, IQR) while at FU it was 92 (range 37.5&#x02013;100).</p><p id="Par34">Major clinical and MRI characteristics of each patient are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Major clinical and MRI characteristics of each DM1 patient</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">sex</th><th align="left">Age at disease onset (years)</th><th align="left">CTG expansion class</th><th align="left">CTG average expansion</th><th align="left">Disease duration (years)</th><th align="left">Age at 1st MRI (years)</th><th align="left">Age at 2nd MRI (years)</th><th align="left">Follow-up duration (month)</th><th align="left">MIRS at 1st MRI</th><th align="left">MIRS at 2nd MRI</th></tr></thead><tbody><tr><td align="left"><italic>P1</italic></td><td align="left">M</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">825</td><td char="." align="char">43</td><td char="." align="char">43</td><td char="." align="char">45</td><td char="." align="char">32</td><td char="." align="char">4</td><td char="." align="char">4</td></tr><tr><td align="left"><italic>P2</italic></td><td align="left">F</td><td char="." align="char">20</td><td char="." align="char">2</td><td char="." align="char">475</td><td char="." align="char">5</td><td char="." align="char">25</td><td char="." align="char">27</td><td char="." align="char">21</td><td char="." align="char">2</td><td char="." align="char">2</td></tr><tr><td align="left"><italic>P3</italic></td><td align="left">M</td><td char="." align="char">51</td><td char="." align="char">1</td><td char="." align="char">70</td><td char="." align="char">4</td><td char="." align="char">55</td><td char="." align="char">59</td><td char="." align="char">53</td><td char="." align="char">2</td><td char="." align="char">2</td></tr><tr><td align="left"><italic>P4</italic></td><td align="left">F</td><td char="." align="char">16</td><td char="." align="char">2</td><td char="." align="char">445</td><td char="." align="char">11</td><td char="." align="char">27</td><td char="." align="char">31</td><td char="." align="char">42</td><td char="." align="char">3</td><td char="." align="char">3</td></tr><tr><td align="left"><italic>P5</italic></td><td align="left">F</td><td char="." align="char">19</td><td char="." align="char">2</td><td char="." align="char">325</td><td char="." align="char">10</td><td char="." align="char">29</td><td char="." align="char">33</td><td char="." align="char">42</td><td char="." align="char">3</td><td char="." align="char">3</td></tr><tr><td align="left"><italic>P6</italic></td><td align="left">M</td><td char="." align="char">18</td><td char="." align="char">2</td><td char="." align="char">575</td><td char="." align="char">2</td><td char="." align="char">20</td><td char="." align="char">23</td><td char="." align="char">37</td><td char="." align="char">3</td><td char="." align="char">3</td></tr><tr><td align="left"><italic>P7</italic></td><td align="left">M</td><td char="." align="char">47</td><td char="." align="char">2</td><td char="." align="char">210</td><td char="." align="char">10</td><td char="." align="char">57</td><td char="." align="char">60</td><td char="." align="char">37</td><td char="." align="char">4</td><td char="." align="char">5</td></tr><tr><td align="left"><italic>P8</italic></td><td align="left">M</td><td char="." align="char">53</td><td char="." align="char">2</td><td char="." align="char">575</td><td char="." align="char">1</td><td char="." align="char">54</td><td char="." align="char">57</td><td char="." align="char">37</td><td char="." align="char">3</td><td char="." align="char">3</td></tr><tr><td align="left"><italic>P9</italic></td><td align="left">F</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">1250</td><td char="." align="char">26</td><td char="." align="char">26</td><td char="." align="char">31</td><td char="." align="char">50</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left"><italic>P10</italic></td><td align="left">F</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">1000</td><td char="." align="char">18</td><td char="." align="char">18</td><td char="." align="char">22</td><td char="." align="char">50</td><td char="." align="char">3</td><td char="." align="char">3</td></tr><tr><td align="left"><italic>P11</italic></td><td align="left">M</td><td char="." align="char">16</td><td char="." align="char">2</td><td char="." align="char">485</td><td char="." align="char">15</td><td char="." align="char">31</td><td char="." align="char">34</td><td char="." align="char">37</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left"><italic>P12</italic></td><td align="left">M</td><td char="." align="char">30</td><td char="." align="char">2</td><td char="." align="char">500</td><td char="." align="char">24</td><td char="." align="char">54</td><td char="." align="char">57</td><td char="." align="char">42</td><td char="." align="char">4</td><td char="." align="char">4</td></tr><tr><td align="left"><italic>P13</italic></td><td align="left">M</td><td char="." align="char">35</td><td char="." align="char">2</td><td char="." align="char">425</td><td char="." align="char">6</td><td char="." align="char">41</td><td char="." align="char">43</td><td char="." align="char">33</td><td char="." align="char">2</td><td char="." align="char">3</td></tr><tr><td align="left"><italic>P14</italic></td><td align="left">F</td><td char="." align="char">19</td><td char="." align="char">2</td><td char="." align="char">750</td><td char="." align="char">34</td><td char="." align="char">53</td><td char="." align="char">57</td><td char="." align="char">50</td><td char="." align="char">4</td><td char="." align="char">4</td></tr><tr><td align="left"><italic>P15</italic></td><td align="left">M</td><td char="." align="char">28</td><td char="." align="char">2</td><td char="." align="char">560</td><td char="." align="char">8</td><td char="." align="char">36</td><td char="." align="char">39</td><td char="." align="char">38</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left"><italic>P16</italic></td><td align="left">F</td><td char="." align="char">42</td><td char="." align="char">1</td><td char="." align="char">73</td><td char="." align="char">0</td><td char="." align="char">42</td><td char="." align="char">44</td><td char="." align="char">30</td><td char="." align="char">1</td><td char="." align="char">1</td></tr><tr><td align="left"><italic>P17</italic></td><td align="left">F</td><td char="." align="char">29</td><td char="." align="char">2</td><td char="." align="char">292</td><td char="." align="char">11</td><td char="." align="char">40</td><td char="." align="char">44</td><td char="." align="char">48</td><td char="." align="char">3</td><td char="." align="char">3</td></tr><tr><td align="left"><italic>P18</italic></td><td align="left">M</td><td char="." align="char">75</td><td char="." align="char">1</td><td char="." align="char">62</td><td char="." align="char">0</td><td char="." align="char">75</td><td char="." align="char">79</td><td char="." align="char">49</td><td char="." align="char">2</td><td char="." align="char">2</td></tr><tr><td align="left"><italic>P19</italic></td><td align="left">F</td><td char="." align="char">81</td><td char="." align="char">1</td><td char="." align="char">50</td><td char="." align="char">0</td><td char="." align="char">81</td><td char="." align="char">84</td><td char="." align="char">32</td><td char="." align="char">2</td><td char="." align="char">2</td></tr><tr><td align="left"><italic>P20</italic></td><td align="left">M</td><td char="." align="char">12</td><td char="." align="char">2</td><td char="." align="char">500</td><td char="." align="char">26</td><td char="." align="char">38</td><td char="." align="char">40</td><td char="." align="char">25</td><td char="." align="char">3</td><td char="." align="char">3</td></tr><tr><td align="left"><italic>P21</italic></td><td align="left">M</td><td char="." align="char">44</td><td char="." align="char">2</td><td char="." align="char">350</td><td char="." align="char">3</td><td char="." align="char">47</td><td char="." align="char">50</td><td char="." align="char">35</td><td char="." align="char">3</td><td char="." align="char">3</td></tr><tr><td align="left"><italic>P22</italic></td><td align="left">F</td><td char="." align="char">35</td><td char="." align="char">2</td><td char="." align="char">350</td><td char="." align="char">8</td><td char="." align="char">43</td><td char="." align="char">46</td><td char="." align="char">35</td><td char="." align="char">3</td><td char="." align="char">3</td></tr><tr><td align="left"><italic>P23</italic></td><td align="left">F</td><td char="." align="char">27</td><td char="." align="char">2</td><td char="." align="char">425</td><td char="." align="char">6</td><td char="." align="char">33</td><td char="." align="char">35</td><td char="." align="char">25</td><td char="." align="char">3</td><td char="." align="char">3</td></tr><tr><td align="left"><italic>P24</italic></td><td align="left">F</td><td char="." align="char">24</td><td char="." align="char">2</td><td char="." align="char">640</td><td char="." align="char">9</td><td char="." align="char">33</td><td char="." align="char">35</td><td char="." align="char">25</td><td char="." align="char">3</td><td char="." align="char">3</td></tr><tr><td align="left"><italic>P25</italic></td><td align="left">M</td><td char="." align="char">10</td><td char="." align="char">2</td><td char="." align="char">489</td><td char="." align="char">13</td><td char="." align="char">23</td><td char="." align="char">27</td><td char="." align="char">46</td><td char="." align="char">2</td><td char="." align="char">2</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec8"><title>STIR and T1 analyses</title><p id="Par35">At BL, 19 patients (76%) showed at least two STIR-positive muscles. The mean STIR% score was 12.8% in lower body (STIR%LB) (range 0&#x02013;39.1%, IQR 1.6&#x02013;18) while in upper body (STIR%UB) was 1.6% (range 0&#x02013;9.1%, IQR 0&#x02013;1.5). FU MRI analysis showed STIR alterations in at least two muscles in 22 patients (88%), with a mean STIR%LB of 20.1% (range 0&#x02013;40.6%, IQR 10.2&#x02013;31.7) and median STIR%UB score of 5.3% (range 0&#x02013;48.5%, IQR 0&#x02013;7.6), and an overall STIR% mean score of 14.9% (range 0&#x02013;43.3, IQR 7.7&#x02013;21.1). Global &#x00394;STIR% was 6% between first and last MRI (range 0&#x02013;25.8%). Two patients with completely normal MRI at baseline (STIR negative, T1 negative) showed STIR positivity in some muscles of the legs at FU without fat replacement.</p><p id="Par36">T1 sequence analysis revealed mean T1-score of 55.4 at BL (range 0&#x02013;183, IQR 8.5&#x02013;105.5) and a mean T1-score of 69.8 at FU (range 1&#x02013;183, IQR 19&#x02013;128.5), corresponding to a mean progression of overall T1-score (&#x00394;T1%) of 3.1% (range 0&#x02013;16.7%). Mean overall progression was 3.9% for LB (&#x00394;T1-LB&#x02009;=&#x02009;1.3% per year) (range 0&#x02013;19.1%) and 1.5% for UB (&#x00394;T1-UB&#x02009;=&#x02009;0.5% per year) (range 0&#x02013;12.1%) muscles. Considering all patients, the mean &#x00394;T1%-LB per year was 1.28%, ranging from 0 to 6.03%. There was a significant progression of T1-score (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) and T1% (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) at FU considering all muscles. Five patients (20%) did not show any T1-score progression (&#x00394;T1&#x02009;=&#x02009;0). In these patients the mean time-lapse between MRIs was significantly shorter compared to the twenty patients who progressed (28&#x000a0;months vs 40&#x000a0;months respectively, <italic>p</italic>&#x02009;=&#x02009;0.003). By contrast, among the 20 patients showing some degree of fat replacement progression, the % of T1-score progression per year differs among patients. Nine patients (36%) showed a mild progression (0&#x02013;1% T1-score progression per year), seven patients (28%) showed a moderate progression (1&#x02013;3% per year) and four patients (16%) showed a fast progression (&#x0003e;&#x02009;3% per year) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A). The rate of fat replacement progression did not show any correlation with disease severity and duration, age, gender or genetical background.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>T1-score and Atrophy-score progression. On the left, overall T1- (<bold>A</bold>) and Atrophy-score (<bold>B</bold>) variation at FU for each patient. In the middle, T1- (<bold>A</bold>) and Atrophy-score (<bold>B</bold>) variation for each patient according to months at follow-up MRI. On the right, graphic representation of percentage of non-, mild-, moderate- and fast progressors</p></caption><graphic xlink:href="415_2024_12544_Fig1_HTML" id="MO1"/></fig></p><p id="Par37">The leg muscles showed the higher T1-score progression at FU. Muscles with higher degree of progression of fat replacement (&#x0003e;&#x02009;3%) in LB were: <italic>gastrocnemius medialis</italic> (mean &#x00394;T1-score%&#x02009;+&#x02009;10&#x02013;11%), followed by <italic>soleus</italic> (7&#x02013;10%), <italic>flexor hallucis longus</italic> (8%), <italic>gastrocnemius lateralis</italic> (7&#x02013;8%), <italic>tibialis anterior</italic> (6&#x02013;8%), <italic>vastus medialis</italic> (6&#x02013;8%) and <italic>iliocostalis lumborum</italic> (4&#x02013;6%), followed by the lumbar paraspinal muscles, <italic>biceps femori caput breve</italic>, <italic>rectus abdominis, semitendinosus, tensor fasciae latae, sartorius</italic> and <italic>gluteus minimus</italic>. In UB <italic>trapezius</italic> (4&#x02013;6%), <italic>genioglossus</italic> (4%) and cervical paraspinal muscles (3&#x02013;4%) showed the higher degree of percentage of T1 fat replacement progression.</p></sec><sec id="Sec9"><title>STIR-dependent T1-score progression</title><p id="Par38">T1-score progression significantly correlated with STIR% at BL (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, <italic>r</italic>&#x02009;=&#x02009;0.76) regardless of disease duration (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A). The average &#x00394;T1%-LB per year significantly correlated with STIR- LB score at BL (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, <italic>r</italic>&#x02009;=&#x02009;0.69). In particular fast progression (&#x00394;T1-LB score per year&#x02009;&#x0003e;&#x02009;1%) and ultra-fast progression (&#x00394;T1-LB score per year&#x02009;&#x0003e;&#x02009;3%) significantly correlated with STIR-score at BL regardless of FU duration (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, <italic>r</italic>&#x02009;=&#x02009;0.86 and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, <italic>r</italic>&#x02009;=&#x02009;0.63, respectively). Conversely, no significant correlation was found between non-progression (&#x00394;T1-score LB&#x02009;=&#x02009;0%) and any clinical or MRI features.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>STIR-dependent fat replacement progression. <bold>A</bold> significant correlation between STIR positivity at BL and fat replacement progression at FU (&#x00394;T1%). <bold>B</bold> Number of muscles progressed (blue) and not progressed (red) in T1 sequences at FU, accordingly to STIR positivity/negativity at 1st MRI</p></caption><graphic xlink:href="415_2024_12544_Fig2_HTML" id="MO2"/></fig></p><p id="Par39">Overall, 218 muscle were STIR positive at BL, 102 of which (46.8%) showed some degree of T1-score progression (at least 1 point of Mercuri scale) at the 2nd MRI study. Of the 2207 STIR-negative muscles at BL, 235 (10.7%) showed a T1-score progression at FU (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) (Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B and <xref rid="Fig3" ref-type="fig">3</xref>). On the other hand, the total amount of muscles that showed T1 progression at FU, regardless of STIR positivity at first MRI, was 337 muscles. Of these, 102 were STIR positive at the BL (30.2%) while 235 were STIR negative. Interestingly, among the 235 STIR-negative muscles at BL that showed T1 progression, 71 became STIR positive at FU.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Muscle MRI findings. Axial plane of lower limbs in STIR and T1 sequences at BL and FU: STIR-positive right vastus medialis and left soleus at BL (yellow arrows) showed fat replacement progression in T1 sequences at FU study (red arrowheads) and still STIR-positive signal at FU (orange arrows); similarly STIR-positive right tibialis anterior at BL (yellow asterisks) showed T1 progression with complete fat replacement (red asterisks) but STIR negative (orange dot) at FU (P15, 36&#x000a0;years-old male at first MRI, FU duration 38&#x000a0;months, MIRS 3, E2 expansion class)</p></caption><graphic xlink:href="415_2024_12544_Fig3_HTML" id="MO3"/></fig></p><p id="Par40">The heatmap analysis shows a good overlap between STIR-positive muscles and fat replaced muscles in T1 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Segmental Heatmap. Overlapped STIR positivity (red or not) and T1-score (blue scale) of at BL and at FU for each patient and each muscle; note the good overlapping between T1 progression (darker blu) at FU and STIR positivity at BL and FU</p></caption><graphic xlink:href="415_2024_12544_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec10"><title>STIR-independent atrophy progression</title><p id="Par41">Sixteen patients showed atrophy in at least one muscle or compartment at BL, 19 at follow-up. Mean value of overall atrophy was 6.4 at BL (range 0&#x02013;22) and 9.2 at FU (range 0&#x02013;33) (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001).</p><p id="Par42">At BL, 17 patients showed some degree of atrophy of at least one UB muscle, while only 7 patients had atrophy of at least one muscle of LB compartments. At FU, 18 patients showed atrophy in UB, while 13 patients had some degree of atrophy of at least one LB compartment.</p><p id="Par43">All patients showing muscle atrophy progression had some degree of muscle atrophy in at least one UB muscle at BL. Considering LB, only seven patients showed atrophy in at least one compartment at BL.</p><p id="Par44">Overall mean progression was 4% (range 0&#x02013;15.2%) (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), 5% in UB (range 0&#x02013;35%) while in 3% in LB (range 0&#x02013;20%) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B).</p><p id="Par45">Fifteen out of twenty-three patients (65%) showed some degree of atrophy progression in UB at FU. None of the muscles of UB that showed an atrophy progression at FU was STIR positive at BL (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). Conversely, in LB, atrophy progression was also associated with fat replacement progression. Thigh atrophy was detected in right vastus medialis of two patients at baseline, both showed a 1-point progression during FU. One showed 1-point T1 progression (2 to 3) and also STIR positivity at BL and FU; the other showed no fat replacement at both MRIs, neither STIR hyperintensity. One more patient developed thigh atrophy at FU.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Atrophy progression. STIR-independent atrophy-progression of pectoralis minor at first (up) and last (down) MRI study after 37&#x000a0;months (P6, 20&#x000a0;years-old male, FU duration 37, months, MIRS 3, E2 expansion class)</p></caption><graphic xlink:href="415_2024_12544_Fig5_HTML" id="MO5"/></fig></p><p id="Par46">Atrophy-score in UB at BL and FU significantly correlated with MIRS score (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p></sec><sec id="Sec11"><title>Clinical-MRI correlations</title><p id="Par47">Overall T1-score at BL correlated with disease duration at both MRI studies (<italic>p</italic>&#x02009;=&#x02009;0.007, <italic>r</italic>&#x02009;=&#x02009;0.52) and also with MIRS at BL and at FU (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>r</italic>&#x02009;=&#x02009;0.72 and 0.75).</p><p id="Par48">T1 score at FU correlated with disease duration (<italic>p</italic>&#x02009;=&#x02009;0.007, <italic>r</italic>&#x02009;=&#x02009;0.52). Both T1-score at FU and &#x00394;T1-score correlated with MIRS at BL and at FU (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>r</italic>&#x02009;=&#x02009;0.77 and <italic>p</italic>&#x02009;=&#x02009;0.009, <italic>r</italic>&#x02009;=&#x02009;0.51, respectively). Noteworthy among the 80% of patients who showed some degree of T1-score progression at FU, only 16% showed MIRS progression at FU. MIRS progression at FU significantly correlated with &#x00394;T1-score (<italic>p</italic>&#x02009;=&#x02009;0.004, <italic>r</italic>&#x02009;=&#x02009;0.57) and STIR-score at BL (<italic>p</italic>&#x02009;=&#x02009;0.04, <italic>r</italic>&#x02009;=&#x02009;0.41), but not with atrophy score.</p><p id="Par49">In general, we did not find any correlation between T1 score variation (&#x00394;T1-score) and time-lapse between MRIs.</p><p id="Par50">STIR% at BL correlated with disease duration at first MRI (<italic>p</italic>&#x02009;=&#x02009;0.007, <italic>r</italic>&#x02009;=&#x02009;0.53). STIR% at BL showed also a significant correlation with MIRS at both BL (<italic>p</italic>&#x02009;=&#x02009;0.001 <italic>r</italic>&#x02009;=&#x02009;0.72) and FU (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>r</italic>&#x02009;=&#x02009;0.7). Interestingly also STIR% at FU showed a good correlation with MIRS at FU (<italic>p</italic>&#x02009;=&#x02009;0.001, <italic>r</italic>&#x02009;=&#x02009;0.61).</p><p id="Par51">MRC at BL and at FU correlated with T1-score at both timepoints (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>r</italic>&#x02009;=&#x02009;0.74 and <italic>r</italic>&#x02009;=&#x02009;0.75). MRC also correlated with atrophy scores, at BL (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>r</italic>&#x02009;=&#x02009;0.85) and at FU (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>r</italic>&#x02009;=&#x02009;0.86), and with STIR% at BL (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>r</italic>&#x02009;=&#x02009;0.74) and at FU (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>r</italic>&#x02009;=&#x02009;0.77).</p><p id="Par52">For correlation analysis we also evaluated LB-MRC (MRC-60) with respect to T1-LB score and we found a significant correlation at BL (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>r</italic>&#x02009;=&#x02009;0.74) and at FU (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>r</italic>&#x02009;=&#x02009;0.78).</p><p id="Par53">&#x00394;T1-score only correlated with MRC-100 at FU (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, <italic>r</italic>&#x02009;=&#x02009;0.5), while &#x00394;MRC correlated with T1-score at BL and at FU (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, <italic>r</italic>&#x02009;=&#x02009;0.42 and <italic>r</italic>&#x02009;=&#x02009;0.45) but not with &#x00394;T1-score.</p><p id="Par54">CTG average expansion correlated with age at disease onset (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>r</italic>&#x02009;=&#x02009;&#x02212;&#x02009;0.72), with MIRS at BL (<italic>p</italic>&#x02009;=&#x02009;0.01 <italic>r</italic> 0.5) and at FU (<italic>p</italic>&#x02009;=&#x02009;0.008 <italic>r</italic>&#x02009;=&#x02009;0.52), and with MRC-100 at BL (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, <italic>r</italic>&#x02009;=&#x02009;0.68) and at FU (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, <italic>r</italic>&#x02009;=&#x02009;0.62), but did not correlate with any MRI parameters.</p><p id="Par55">Linear regression analysis showed that there were no correlation between &#x00394;T1% with time-lapse between MRIs, age, age at disease onset, CTG expansion and disease duration.</p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par56">This prospective, longitudinal study provides 3-year FU data on a cohort of clinically and genetically characterized DM1 patients, combining semiquantitative T1 muscle MRI evaluation for fat replacement and muscle atrophy, and the assessment of STIR hyperintensity, with genetic and clinical measures. Natural history of fat replacement and muscle damage in DM1 patients is of key importance for upcoming clinical trials, especially for the role that muscle MRI could have as a biomarker of disease progression. To date, there are no longitudinal MRI studies in DM1 patients.</p><p id="Par57">Our results showed significant changes in all MRI parameters evaluated and a significant correlation between MRI and clinical characteristics, such as disease duration, MRC and MIRS. We found that fat replacement progression was more evident in LB (1.3% of T1-score per year) compared to UB (0.5% per year) but conversely that atrophy progression was more evident in UB (5%) compared to lower body (3%).</p><p id="Par58">Interestingly we observed that the rate of fat replacement progression differs among patients, from non-progressors (&#x00394;T1-score&#x02009;=&#x02009;0) to fast progressors (&#x0003e;&#x02009;3% per year). These findings does not correlate with any demographic, clinical or genetical background, suggesting other underlying mechanisms influencing disease progression in DM1. Moreover, it could be hypothesized that disease progression in DM1 could not have a constant rate along life, but vary with periods of stability and periods of progression. Nevertheless, this hypothesis have to be supported by further evidences.</p><p id="Par59">Muscles with a higher rate of fat replacement progression are the earliest affected muscles, according to the pattern of muscle involvement in DM1, suggesting that some muscles (e.g. <italic>gastrocnemius medialis</italic>, <italic>quadriceps</italic>) are the most sensitive muscles in monitoring disease onset and progression, as also previously reported [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR22">22</xref>], in particular <italic>gastrocnemius medialis</italic> for the early stages of disease (including asymptomatic and pre-symptomatic) and <italic>quadriceps</italic> for the advanced stages of the disease.</p><p id="Par60">Another important aspect of the study is the confirmation of the sensitivity and specificity of muscle MRI in predicting fat replacement and disease progression. In fact, we found a strong correlation between fat replacement progression and MIRS progression. Moreover, we found a good correlation between STIR positivity at baseline and MIRS progression at FU. Noteworthy, we observed that only 20% of patients showing T1-score progression also had a MIRS progression at FU, suggesting that muscle MRI is more sensitive than clinical scales in detecting disease activity and progression. Moreover, since we used a semiquantitative scale for muscle MRI scoring, we were able to catch only the major MRI changes, able to modify the Mercuri score, probably underestimating the power of a quantitative imaging technique in detecting even minimal disease progression.</p><p id="Par61">We observed a strong correlation between STIR positivity at baseline (STIR%) and both fat replacement progression (&#x00394;T1) and clinical worsening (&#x00394;MRC) suggesting the high sensitivity of STIR positivity as a prognostic indicator of high risk of disease progression.</p><p id="Par62">This study confirms the hypothesis we proposed in our first cross-sectional study [<xref ref-type="bibr" rid="CR9">9</xref>] concerning the fat replacement progression of STIR-positive muscles. We found a strong correlation between STIR positivity at BL and fat replacement progression at FU, demonstrating that STIR positivity precedes fat replacement also in DM1, as it occurs in other muscular dystrophies or inflammatory myopathies [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. STIR hyperintensity also shows the same pattern of muscle involvement of T1, as shown by the heatmaps and had a good correlation with clinical scales at both timepoints.</p><p id="Par63">Almost half of STIR-positive muscles at BL showed some degree of T1-score progression at FU, while only 10% of STIR-negative muscles at BL showed a T1-score progression at FU. Interestingly 30% of these muscles were STIR positive at FU, suggesting that they became STIR positive some time between the first and second MRI, supporting the evidence that STIR positivity is associated with fat replacement. For the remaining muscle that showed STIR-independent progression of fat replacement, the most probable explication is that semiquantitative T1 scoring is not enough to detect minimal changes, which could have been probably detected by quantitative Dixon acquisition. Alternatively, other hypothesis can be made: (1) STIR positivity could occur for very short periods not enough to be detected by MRI studies lasting 3&#x000a0;years of FU, but influencing fat replacement progression; (2) other pathophysiological mechanisms leading to fat replacement occurs in muscles bypassing pathways causing STIR positivity; (3) low MRI observer reliability.</p><p id="Par64">One other important piece of evidence about STIR sequences is that among patients with normal muscle MRI at baseline (STIR negative, T1 negative), two of them showed only STIR-positive muscle at FU in the legs, identifying for these patients the onset of disease activity, marking the transition from an asymptomatic stage of disease to a pre-symptomatic stage of disease.</p><p id="Par65">On the other hand, half of STIR-positive muscle did not show fat replacement progression. It could be explicated by the fact that the rate of fat replacement progression could differ among muscles, and some muscles could require longer observation periods to detect fat replacement progression; moreover, STIR positivity could start in proximity of MRI study, and time-lapse between two MRI studies could not be enough to lead to fat replacement; finally, STIR positivity could be a reversible process, interrupted by other endogenous or exogenous mechanisms before fat replacement occurrence.</p><p id="Par66">What there is behind STIR positivity in DM1 is not known since there is no evidence of an inflammatory process behind muscle degeneration in DM1 muscle biopsies. Anyway, STIR positivity reflects not only inflammation, but also muscle edema, which could also be the consequence of necrosis and regeneration, or vascular or neurogenic alteration [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. It represents a reversible marker of disease activity, often predicting T1 changes over time and it is associated with clinical worsening. For this reason, STIR hyperintensity could be useful in identifying those muscles potentially susceptible of targeted disease-modifying therapies, representing a sensitive biomarker of early disease activity in DM1 for upcoming clinical trials.</p><p id="Par67">Finally, muscle atrophy could represent another important mechanism underlying muscle weakness in DM1. In fact, we observed that muscle atrophy progression is independent of STIR positivity and fat replacement in UB, with respect to the LB where the atrophy follows fat replacement. Both atrophy and atrophy progression are more evident in UB muscles, especially <italic>trapezius</italic>, <italic>sternocleidomastoideus</italic>, and <italic>pectoralis minor</italic>. This study confirms that in UB, muscle atrophy and atrophy progression are independent from fat replacement, suggesting additional mechanisms of muscle wasting in DM1. By contrast, in LB, muscle atrophy is associated with fat replacement, as it occurs in other muscular dystrophies and spinal muscular atrophy [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. In LB, atrophy score degree and progression was more evident for leg posterior compartment, following the distribution of STIR hyperintensity and T1 fat replacement; anyway, also <italic>tibialis posterior</italic> volume was previously found to decreased overtime in DM1 patients compared to healthy subjects [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par68">Even if we observed a good correlation between atrophy score in UB and clinical severity, as observed by other authors [<xref ref-type="bibr" rid="CR30">30</xref>], no correlation with disease progression or clinical worsening were found, suggesting that more data are needed to establish whether or not it could represent a good parameter for disease progression. Of note, atrophy evaluation included <italic>sternocleidomastoideus</italic>, <italic>trapezius</italic>, <italic>pectoralis minor</italic> and <italic>major</italic> on the basis of previous findings [<xref ref-type="bibr" rid="CR9">9</xref>]: there can be also considered trunk muscles, with an antigravity action, known to have a good correlation with postural stability or balance in patients with muscular dystrophies [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. However, differently from our findings, these studies found a continuum between fat infiltration, edema and muscle size in trunk muscles analysed. It could be explained by the difference in evaluated muscles: maybe abdominal muscles, <italic>erector spinae</italic> and <italic>psoas</italic> follow the same pathological changes of LB muscles of our study, in which T1 fat infiltration seems to have a role in atrophy progression, while <italic>sternocleidomastoideus</italic>, <italic>trapezius</italic>, <italic>pectoralis minor</italic> and <italic>major</italic> undergo atrophy without additional MRI changes, maybe following different pathological mechanisms.</p><p id="Par69">A last consideration concerns the influence of disease duration on disease progression. In our cohort, even if non-progressors had a significantly shorter FU, we did not find any correlation between time-lapse between MRIs and T1 score variation (&#x00394;T1-score), suggesting that other factors independent by disease duration influence the rate of fat replacement and disease progression in patients. This data let us suppose that in the natural history of the disease, periods of disease activity and progression could alternate with periods of disease quiescence, possibly influenced by endogenous or exogenous factors, as it occurs in disease onset, after a long period of quiescence after birth. Moreover, no correlations were found between MRI changes overtime and CTG expansion. Even if some cross-sectional studies found a correlation between MRI alterations and CTG expansion [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>], we evaluated fat replacement progression (i.e. &#x00394;T1%) overtime in patients with different age, in different stages of the disease, in which the occurrence of somatic mosaicism and triplet repeat expansion instability could even increase the diversity, also considering that the genetic diagnosis and MRI studies were performed at different times.</p><p id="Par70">This study has several limitations that deserve to be mentioned: (1) the first, and most important, is the use of a semiquantitative scoring of MRI: even if we have been able to demonstrate the higher sensitivity of MRI with respect to clinical evaluation and clinical scales to detect disease activity and progression, quantitative MRI acquisition would be even more sensitive to detect minimal changes before clinical worsening and should be preferred for clinical trials; (2) small sample size: clinical and MRI data could be influenced by several factors such as phenotypical variability, age of patients, disease duration and stage, that could underestimate some MRI-clinical association because of lacking statistical power; (3) inhomogeneous FU duration: even if we normalized the MRI findings for time-lapse between MRIs, clinical assessment and correspondent MRI features would have been more comparable and reliable between patients with even more similar observation period; (4) clinical and genetic heterogeneity of the sample, in terms of disease severity at baseline and CTG average expansion.</p></sec><sec id="Sec13"><title>Conclusion</title><p id="Par71">Muscle MRI is a sensitive biomarker of disease activity, severity, and progression in DM1 and it is more accurate than clinical evaluation, also for the milder spectrum of disease. Fat replacement and progression in more evident in the LB, while muscle atrophy progression is more evident in UB regardless of STIR positivity and fat replacement. STIR positivity precedes fat replacement and represents a biomarker of disease activity, also in the early stages of the disease, helping to identify the disease onset in asymptomatic patients. STIR positivity at BL correlates with fat replacement progression and clinical worsening at FU, identifying patients with higher risk of disease progression. It can identify those muscles with a potentially reversible pathological process, representing a promising biomarker of disease activity. Muscle MRI assessment should be introduced routinely in forthcoming clinical trials&#x02019; design, representing a sensitive and reliable biomarker able to capture minimal muscle changes in a short period.</p></sec></body><back><notes notes-type="author-contribution"><title>Author contributions</title><p>LF and MG: study design, analysis and interpretation of clinical and neuroimaging data, manuscript writing, and responsibility for the integrity of the study; GA: study concept; LL: analysis and interpretation of clinical and neuroimaging data, statistical analysis, and responsibility for the integrity of the study; LT: patients&#x02019; clinical evaluation, analysis and interpretation of neuroimaging studies, and revision of the manuscript for intellectual content; AL, SM, GM, and RC: patients&#x02019; clinical evaluation and critical revision of the manuscript for intellectual content; ER, FF, DM, DSA, and EB: database creation and data reporter, and critical revision of data collection; MS and GA: study design and supervision and critical revision of the manuscript for intellectual content; MG: study concept, analysis and interpretation of clinical and neuroimaging data, statistical analysis, drafting and revising manuscript, and local study supervisor. All authors have read and approved the submission.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Universit&#x000e0; degli Studi di Roma La Sapienza within the CRUI-CARE Agreement.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data related to this study are available upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflicts of interest</title><p id="Par72">The authors report no competing interests.</p></notes><notes id="FPar2"><title>Ethical standards statement</title><p id="Par73">The study was approved by local ethic committee and had been performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. Specific national laws were observed.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Udd</surname><given-names>B</given-names></name><name><surname>Krahe</surname><given-names>R</given-names></name></person-group><article-title>The myotonic dystrophies: molecular, clinical, and therapeutic challenges</article-title><source>Lancet Neurol</source><year>2012</year><volume>11</volume><fpage>891</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(12)70204-1</pub-id><pub-id pub-id-type="pmid">22995693</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Udd B, Krahe R (2012) The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 11:891&#x02013;905<pub-id pub-id-type="pmid">22995693</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Bucci</surname><given-names>E</given-names></name><name><surname>Testa</surname><given-names>M</given-names></name><name><surname>Licchelli</surname><given-names>L</given-names></name><etal/></person-group><article-title>A 34-year longitudinal study on long-term cardiac outcomes in DM1 patients with normal ECG at baseline at an Italian clinical centre</article-title><source>J Neurol</source><year>2018</year><volume>265</volume><issue>4</issue><fpage>885</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1007/s00415-018-8773-3</pub-id><pub-id pub-id-type="pmid">29429070</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Bucci E, Testa M, Licchelli L et al (2018) A 34-year longitudinal study on long-term cardiac outcomes in DM1 patients with normal ECG at baseline at an Italian clinical centre. J Neurol 265(4):885&#x02013;895. 10.1007/s00415-018-8773-3<pub-id pub-id-type="pmid">29429070</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Timchenko</surname><given-names>L</given-names></name></person-group><article-title>Molecular mechanisms of muscle atrophy in myotonic dystrophies</article-title><source>Int J Biochem Cell Biol</source><year>2013</year><volume>45</volume><issue>10</issue><fpage>2280</fpage><lpage>2287</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2013.06.010</pub-id><pub-id pub-id-type="pmid">23796888</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Timchenko L (2013) Molecular mechanisms of muscle atrophy in myotonic dystrophies. Int J Biochem Cell Biol 45(10):2280&#x02013;2287. 10.1016/j.biocel.2013.06.010. (<bold>Epub 2013 Jun 21</bold>)<pub-id pub-id-type="pmid">23796888</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Ten Dam</surname><given-names>L</given-names></name><name><surname>van der Kooi</surname><given-names>AJ</given-names></name><name><surname>Verhamme</surname><given-names>C</given-names></name><etal/></person-group><article-title>Muscle imaging in inherited and acquired muscle diseases</article-title><source>Eur J Neurol</source><year>2016</year><volume>23</volume><fpage>688</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1111/ene.12984</pub-id><pub-id pub-id-type="pmid">27000978</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Ten Dam L, van der Kooi AJ, Verhamme C et al (2016) Muscle imaging in inherited and acquired muscle diseases. Eur J Neurol 23:688&#x02013;703. 10.1111/ene.12984<pub-id pub-id-type="pmid">27000978</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x000ed;az-Manera</surname><given-names>J</given-names></name><name><surname>Llauger</surname><given-names>J</given-names></name><name><surname>Gallardo</surname><given-names>E</given-names></name><name><surname>Illa</surname><given-names>I</given-names></name></person-group><article-title>Muscle MRI in muscular dystrophies</article-title><source>Acta Myol</source><year>2015</year><volume>34</volume><issue>2&#x02013;3</issue><fpage>95</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">27199536</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">D&#x000ed;az-Manera J, Llauger J, Gallardo E, Illa I (2015) Muscle MRI in muscular dystrophies. Acta Myol 34(2&#x02013;3):95&#x02013;108<pub-id pub-id-type="pmid">27199536</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Warman-Chardon</surname><given-names>J</given-names></name><name><surname>Diaz-Manera</surname><given-names>J</given-names></name><name><surname>Tasca</surname><given-names>G</given-names></name><etal/></person-group><article-title>247th ENMC International Workshop: muscle magnetic resonance imaging&#x02014;implementing muscle MRI as a diagnostic tool for rare genetic myopathy cohorts. Hoofddorp, The Netherlands, September 2019</article-title><source>Neuromuscul Disord</source><year>2020</year><volume>30</volume><fpage>938</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2020.08.360</pub-id><pub-id pub-id-type="pmid">33004285</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Warman-Chardon J, Diaz-Manera J, Tasca G et al (2020) 247th ENMC International Workshop: muscle magnetic resonance imaging&#x02014;implementing muscle MRI as a diagnostic tool for rare genetic myopathy cohorts. Hoofddorp, The Netherlands, September 2019. Neuromuscul Disord 30:938&#x02013;947. 10.1016/j.nmd.2020.08.360<pub-id pub-id-type="pmid">33004285</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Heskamp</surname><given-names>L</given-names></name><name><surname>van Nimwegen</surname><given-names>M</given-names></name><name><surname>Ploegmakers</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Lower extremity muscle pathology in myotonic dystrophy type 1 assessed by quantitative MRI</article-title><source>Neurology</source><year>2019</year><volume>92</volume><issue>24</issue><fpage>e2803</fpage><lpage>e2814</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000007648</pub-id><pub-id pub-id-type="pmid">31118244</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Heskamp L, van Nimwegen M, Ploegmakers MJ et al (2019) Lower extremity muscle pathology in myotonic dystrophy type 1 assessed by quantitative MRI. Neurology 92(24):e2803&#x02013;e2814. 10.1212/WNL.0000000000007648<pub-id pub-id-type="pmid">31118244</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LH</given-names></name><name><surname>Shaw</surname><given-names>DWW</given-names></name><name><surname>Faino</surname><given-names>A</given-names></name><name><surname>Budech</surname><given-names>CB</given-names></name><name><surname>Lewis</surname><given-names>LM</given-names></name><name><surname>Statland</surname><given-names>J</given-names></name><name><surname>Eichinger</surname><given-names>K</given-names></name><name><surname>Tapscott</surname><given-names>SJ</given-names></name><name><surname>Tawil</surname><given-names>RN</given-names></name><name><surname>Friedman</surname><given-names>SD</given-names></name></person-group><article-title>Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy</article-title><source>BMC Musculoskelet Disord</source><year>2021</year><volume>22</volume><issue>1</issue><fpage>262</fpage><pub-id pub-id-type="doi">10.1186/s12891-021-04134-7</pub-id><pub-id pub-id-type="pmid">33691664</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Wang LH, Shaw DWW, Faino A, Budech CB, Lewis LM, Statland J, Eichinger K, Tapscott SJ, Tawil RN, Friedman SD (2021) Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy. BMC Musculoskelet Disord 22(1):262. 10.1186/s12891-021-04134-7<pub-id pub-id-type="pmid">33691664</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Garibaldi</surname><given-names>M</given-names></name><name><surname>Nicoletti</surname><given-names>T</given-names></name><name><surname>Bucci</surname><given-names>E</given-names></name><name><surname>Fionda</surname><given-names>L</given-names></name><name><surname>Leonardi</surname><given-names>L</given-names></name><name><surname>Morino</surname><given-names>S</given-names></name><name><surname>Tufano</surname><given-names>L</given-names></name><name><surname>Alfieri</surname><given-names>G</given-names></name><name><surname>Lauletta</surname><given-names>A</given-names></name><name><surname>Merlonghi</surname><given-names>G</given-names></name><name><surname>Perna</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>S</given-names></name><name><surname>Ricci</surname><given-names>E</given-names></name><name><surname>Alonso Perez</surname><given-names>J</given-names></name><name><surname>Tartaglione</surname><given-names>T</given-names></name><name><surname>Petrucci</surname><given-names>A</given-names></name><name><surname>Pennisi</surname><given-names>EM</given-names></name><name><surname>Salvetti</surname><given-names>M</given-names></name><name><surname>Cutter</surname><given-names>G</given-names></name><name><surname>D&#x000ed;az-Manera</surname><given-names>J</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Antonini</surname><given-names>G</given-names></name></person-group><article-title>Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): refining muscle involvement and implications for clinical trials</article-title><source>Eur J Neurol</source><year>2022</year><volume>29</volume><issue>3</issue><fpage>843</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1111/ene.15174</pub-id><pub-id pub-id-type="pmid">34753219</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Garibaldi M, Nicoletti T, Bucci E, Fionda L, Leonardi L, Morino S, Tufano L, Alfieri G, Lauletta A, Merlonghi G, Perna A, Rossi S, Ricci E, Alonso Perez J, Tartaglione T, Petrucci A, Pennisi EM, Salvetti M, Cutter G, D&#x000ed;az-Manera J, Silvestri G, Antonini G (2022) Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): refining muscle involvement and implications for clinical trials. Eur J Neurol 29(3):843&#x02013;854. 10.1111/ene.15174. (<bold>Epub 2021 Dec 6</bold>)<pub-id pub-id-type="pmid">34753219</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Heskamp</surname><given-names>L</given-names></name><name><surname>van Nimwegen</surname><given-names>M</given-names></name><name><surname>Ploegmakers</surname><given-names>MJ</given-names></name><name><surname>Bassez</surname><given-names>G</given-names></name><name><surname>Deux</surname><given-names>JF</given-names></name><name><surname>Cumming</surname><given-names>SA</given-names></name><name><surname>Monckton</surname><given-names>DG</given-names></name><name><surname>van Engelen</surname><given-names>BGM</given-names></name><name><surname>Heerschap</surname><given-names>A</given-names></name></person-group><article-title>Lower extremity muscle pathology in myotonic dystrophy type 1 assessed by quantitative MRI</article-title><source>Neurology</source><year>2019</year><volume>92</volume><issue>24</issue><fpage>e2803</fpage><lpage>e2814</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000007648</pub-id><pub-id pub-id-type="pmid">31118244</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Heskamp L, van Nimwegen M, Ploegmakers MJ, Bassez G, Deux JF, Cumming SA, Monckton DG, van Engelen BGM, Heerschap A (2019) Lower extremity muscle pathology in myotonic dystrophy type 1 assessed by quantitative MRI. Neurology 92(24):e2803&#x02013;e2814. 10.1212/WNL.0000000000007648. (<bold>Epub 2019 May 22</bold>)<pub-id pub-id-type="pmid">31118244</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Hiba</surname><given-names>B</given-names></name><name><surname>Richard</surname><given-names>N</given-names></name><name><surname>H&#x000e9;bert</surname><given-names>LJ</given-names></name><name><surname>Cot&#x000e9;</surname><given-names>C</given-names></name><name><surname>Nejjari</surname><given-names>M</given-names></name><name><surname>Vial</surname><given-names>C</given-names></name><name><surname>Bouhour</surname><given-names>F</given-names></name><name><surname>Puymirat</surname><given-names>J</given-names></name><name><surname>Janier</surname><given-names>M</given-names></name></person-group><article-title>Quantitative assessment of skeletal muscle degeneration in patients with myotonic dystrophy type 1 using MRI</article-title><source>J Magn Reson Imaging</source><year>2012</year><volume>35</volume><issue>3</issue><fpage>678</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1002/jmri.22849</pub-id><pub-id pub-id-type="pmid">22069222</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Hiba B, Richard N, H&#x000e9;bert LJ, Cot&#x000e9; C, Nejjari M, Vial C, Bouhour F, Puymirat J, Janier M (2012) Quantitative assessment of skeletal muscle degeneration in patients with myotonic dystrophy type 1 using MRI. J Magn Reson Imaging 35(3):678&#x02013;685. 10.1002/jmri.22849. (<bold>Epub 2011 Nov 8</bold>)<pub-id pub-id-type="pmid">22069222</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Pascual-Gilabert</surname><given-names>M</given-names></name><name><surname>Artero</surname><given-names>R</given-names></name><name><surname>L&#x000f3;pez-Castel</surname><given-names>A</given-names></name></person-group><article-title>The myotonic dystrophy type 1 drug development pipeline: 2022 edition</article-title><source>Drug Discov Today</source><year>2023</year><volume>28</volume><issue>3</issue><fpage>103489</fpage><pub-id pub-id-type="doi">10.1016/j.drudis.2023.103489</pub-id><pub-id pub-id-type="pmid">36634841</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Pascual-Gilabert M, Artero R, L&#x000f3;pez-Castel A (2023) The myotonic dystrophy type 1 drug development pipeline: 2022 edition. Drug Discov Today 28(3):103489. 10.1016/j.drudis.2023.103489. (<bold>Epub 2023 Jan 9</bold>)<pub-id pub-id-type="pmid">36634841</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Fionda</surname><given-names>L</given-names></name><name><surname>Lauletta</surname><given-names>A</given-names></name><name><surname>Leonardi</surname><given-names>L</given-names></name><name><surname>Perez</surname><given-names>JA</given-names></name><name><surname>Morino</surname><given-names>S</given-names></name><name><surname>Merlonghi</surname><given-names>G</given-names></name><name><surname>Alfieri</surname><given-names>G</given-names></name><name><surname>Costanzo</surname><given-names>R</given-names></name><name><surname>Tufano</surname><given-names>L</given-names></name><name><surname>Vanoli</surname><given-names>F</given-names></name><name><surname>Rossini</surname><given-names>E</given-names></name><name><surname>Vigo</surname><given-names>EG</given-names></name><name><surname>Tartaglione</surname><given-names>T</given-names></name><name><surname>Salvetti</surname><given-names>M</given-names></name><name><surname>Antonini</surname><given-names>G</given-names></name><name><surname>Diaz-Manera</surname><given-names>J</given-names></name><name><surname>Garibaldi</surname><given-names>M</given-names></name></person-group><article-title>Muscle MRI in immune-mediated necrotizing myopathy (IMNM): implications for clinical management and treatment strategies</article-title><source>J Neurol</source><year>2023</year><volume>270</volume><issue>2</issue><fpage>960</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1007/s00415-022-11447-7</pub-id><pub-id pub-id-type="pmid">36329184</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Fionda L, Lauletta A, Leonardi L, Perez JA, Morino S, Merlonghi G, Alfieri G, Costanzo R, Tufano L, Vanoli F, Rossini E, Vigo EG, Tartaglione T, Salvetti M, Antonini G, Diaz-Manera J, Garibaldi M (2023) Muscle MRI in immune-mediated necrotizing myopathy (IMNM): implications for clinical management and treatment strategies. J Neurol 270(2):960&#x02013;974. 10.1007/s00415-022-11447-7. (<bold>Epub 2022 Nov 3</bold>)<pub-id pub-id-type="pmid">36329184</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Sherlock</surname><given-names>SP</given-names></name><name><surname>Palmer</surname><given-names>J</given-names></name><name><surname>Wagner</surname><given-names>KR</given-names></name><name><surname>Abdel-Hamid</surname><given-names>HZ</given-names></name><name><surname>Bertini</surname><given-names>E</given-names></name><name><surname>Tian</surname><given-names>C</given-names></name><name><surname>Mah</surname><given-names>JK</given-names></name><name><surname>Kostera-Pruszczyk</surname><given-names>A</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name><name><surname>Guglieri</surname><given-names>M</given-names></name><name><surname>Brandsema</surname><given-names>JF</given-names></name><name><surname>Mercuri</surname><given-names>E</given-names></name><name><surname>Butterfield</surname><given-names>RJ</given-names></name><name><surname>McDonald</surname><given-names>CM</given-names></name><name><surname>Charnas</surname><given-names>L</given-names></name><name><surname>Marraffino</surname><given-names>S</given-names></name></person-group><article-title>Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab</article-title><source>J Neurol</source><year>2022</year><volume>269</volume><issue>8</issue><fpage>4421</fpage><lpage>4435</lpage><pub-id pub-id-type="doi">10.1007/s00415-022-11084-0</pub-id><pub-id pub-id-type="pmid">35396602</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Sherlock SP, Palmer J, Wagner KR, Abdel-Hamid HZ, Bertini E, Tian C, Mah JK, Kostera-Pruszczyk A, Muntoni F, Guglieri M, Brandsema JF, Mercuri E, Butterfield RJ, McDonald CM, Charnas L, Marraffino S (2022) Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab. J Neurol 269(8):4421&#x02013;4435. 10.1007/s00415-022-11084-0. (<bold>Epub 2022 Apr 8</bold>)<pub-id pub-id-type="pmid">35396602</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Monforte</surname><given-names>M</given-names></name><name><surname>Laschena</surname><given-names>F</given-names></name><name><surname>Ottaviani</surname><given-names>P</given-names></name><name><surname>Bagnato</surname><given-names>MR</given-names></name><name><surname>Pichiecchio</surname><given-names>A</given-names></name><name><surname>Tasca</surname><given-names>G</given-names></name><name><surname>Ricci</surname><given-names>E</given-names></name></person-group><article-title>Tracking muscle wasting and disease activity in facioscapulohumeral muscular dystrophy by qualitative longitudinal imaging</article-title><source>J Cachexia Sarcopenia Muscle</source><year>2019</year><volume>10</volume><issue>6</issue><fpage>1258</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.1002/jcsm.12473</pub-id><pub-id pub-id-type="pmid">31668022</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Monforte M, Laschena F, Ottaviani P, Bagnato MR, Pichiecchio A, Tasca G, Ricci E (2019) Tracking muscle wasting and disease activity in facioscapulohumeral muscular dystrophy by qualitative longitudinal imaging. J Cachexia Sarcopenia Muscle 10(6):1258&#x02013;1265. 10.1002/jcsm.12473. (<bold>Epub 2019 Oct 30</bold>)<pub-id pub-id-type="pmid">31668022</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Mathieu</surname><given-names>J</given-names></name><name><surname>Boivin</surname><given-names>H</given-names></name><name><surname>Meunier</surname><given-names>D</given-names></name><name><surname>Gaudreault</surname><given-names>M</given-names></name><name><surname>B&#x000e9;gin</surname><given-names>P</given-names></name></person-group><article-title>Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy</article-title><source>Neurology</source><year>2001</year><volume>56</volume><issue>3</issue><fpage>336</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1212/wnl.56.3.336</pub-id><pub-id pub-id-type="pmid">11171898</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Mathieu J, Boivin H, Meunier D, Gaudreault M, B&#x000e9;gin P (2001) Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 56(3):336&#x02013;340. 10.1212/wnl.56.3.336<pub-id pub-id-type="pmid">11171898</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Garibaldi</surname><given-names>M</given-names></name><name><surname>Tasca</surname><given-names>G</given-names></name><name><surname>Diaz-Manera</surname><given-names>J</given-names></name><etal/></person-group><article-title>Muscle MRI in neutral lipid storage disease (NLSD)</article-title><source>J Neurol</source><year>2017</year><volume>264</volume><issue>7</issue><fpage>1334</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1007/s00415-017-8498-8</pub-id><pub-id pub-id-type="pmid">28503705</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Garibaldi M, Tasca G, Diaz-Manera J et al (2017) Muscle MRI in neutral lipid storage disease (NLSD). J Neurol 264(7):1334&#x02013;1342. 10.1007/s00415-017-8498-8<pub-id pub-id-type="pmid">28503705</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Warman Chardon</surname><given-names>J</given-names></name><name><surname>D&#x000ed;az-Manera</surname><given-names>J</given-names></name><name><surname>Tasca</surname><given-names>G</given-names></name><etal/></person-group><article-title>MYO-MRI diagnostic protocols in genetic myopathies</article-title><source>Neuromuscul Disord</source><year>2019</year><volume>29</volume><issue>11</issue><fpage>827</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2019.08.011</pub-id><pub-id pub-id-type="pmid">31727541</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Warman Chardon J, D&#x000ed;az-Manera J, Tasca G et al (2019) MYO-MRI diagnostic protocols in genetic myopathies. Neuromuscul Disord 29(11):827&#x02013;841. 10.1016/j.nmd.2019.08.011<pub-id pub-id-type="pmid">31727541</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Hollingsworth</surname><given-names>KG</given-names></name><name><surname>de Sousa</surname><given-names>PL</given-names></name><name><surname>Straub</surname><given-names>V</given-names></name><etal/></person-group><article-title>Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1&#x02013;2 October 2009, Paris</article-title><source>France Neuromuscul Disord</source><year>2012</year><volume>22</volume><issue>Suppl 2</issue><fpage>S54</fpage><lpage>S67</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2012.06.005</pub-id><pub-id pub-id-type="pmid">22980769</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Hollingsworth KG, de Sousa PL, Straub V et al (2012) Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1&#x02013;2 October 2009, Paris. France Neuromuscul Disord 22(Suppl 2):S54&#x02013;S67. 10.1016/j.nmd.2012.06.005<pub-id pub-id-type="pmid">22980769</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>D</given-names></name><name><surname>Kley</surname><given-names>RA</given-names></name><name><surname>Strach</surname><given-names>K</given-names></name><etal/></person-group><article-title>Distinct muscle imaging patterns in myofibrillar myopathies</article-title><source>Neurology</source><year>2008</year><volume>71</volume><fpage>758</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000324927.28817.9b</pub-id><pub-id pub-id-type="pmid">18765652</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Fischer D, Kley RA, Strach K et al (2008) Distinct muscle imaging patterns in myofibrillar myopathies. Neurology 71:758&#x02013;765. 10.1212/01.wnl.0000324927.28817.9b<pub-id pub-id-type="pmid">18765652</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Brogna</surname><given-names>C</given-names></name><name><surname>Cristiano</surname><given-names>L</given-names></name><name><surname>Verdolotti</surname><given-names>T</given-names></name><etal/></person-group><article-title>MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients</article-title><source>J Neurol</source><year>2020</year><volume>267</volume><issue>4</issue><fpage>898</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1007/s00415-019-09646-w</pub-id><pub-id pub-id-type="pmid">31776722</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Brogna C, Cristiano L, Verdolotti T et al (2020) MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients. J Neurol 267(4):898&#x02013;912. 10.1007/s00415-019-09646-w<pub-id pub-id-type="pmid">31776722</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>van der Plas</surname><given-names>E</given-names></name><name><surname>Gutmann</surname><given-names>L</given-names></name><name><surname>Thedens</surname><given-names>D</given-names></name><name><surname>Shields</surname><given-names>RK</given-names></name><name><surname>Langbehn</surname><given-names>K</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Sonka</surname><given-names>M</given-names></name><name><surname>Nopoulos</surname><given-names>P</given-names></name></person-group><article-title>Quantitative muscle MRI as a sensitive marker of early muscle pathology in myotonic dystrophy type 1</article-title><source>Muscle Nerve</source><year>2021</year><volume>63</volume><issue>4</issue><fpage>553</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1002/mus.27174</pub-id><pub-id pub-id-type="pmid">33462896</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">van der Plas E, Gutmann L, Thedens D, Shields RK, Langbehn K, Guo Z, Sonka M, Nopoulos P (2021) Quantitative muscle MRI as a sensitive marker of early muscle pathology in myotonic dystrophy type 1. Muscle Nerve 63(4):553&#x02013;562. 10.1002/mus.27174. (<bold>Epub 2021 Feb 5</bold>)<pub-id pub-id-type="pmid">33462896</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Tasca</surname><given-names>G</given-names></name><name><surname>Pescatori</surname><given-names>M</given-names></name><name><surname>Monforte</surname><given-names>M</given-names></name><etal/></person-group><article-title>Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles</article-title><source>PLoS&#x000a0;One</source><year>2012</year><volume>7</volume><issue>6</issue><fpage>e38779</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0038779</pub-id><pub-id pub-id-type="pmid">22719944</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Tasca G, Pescatori M, Monforte M et al (2012) Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles. PLoS&#x000a0;One 7(6):e38779. 10.1371/journal.pone.0038779<pub-id pub-id-type="pmid">22719944</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Pinal-Fernandez</surname><given-names>I</given-names></name><name><surname>Casal-Dominguez</surname><given-names>M</given-names></name><name><surname>Carrino</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity</article-title><source>Ann Rheum Dis</source><year>2017</year><volume>76</volume><issue>4</issue><fpage>681</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2016-210198</pub-id><pub-id pub-id-type="pmid">27651398</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Pinal-Fernandez I, Casal-Dominguez M, Carrino JA et al (2017) Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis 76(4):681&#x02013;687. 10.1136/annrheumdis-2016-210198<pub-id pub-id-type="pmid">27651398</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Paradas</surname><given-names>C</given-names></name><name><surname>Llauger</surname><given-names>J</given-names></name><name><surname>Diaz-Manera</surname><given-names>J</given-names></name><name><surname>Rojas-Garc&#x000ed;a</surname><given-names>R</given-names></name><name><surname>De Luna</surname><given-names>N</given-names></name><name><surname>Iturriaga</surname><given-names>C</given-names></name><name><surname>M&#x000e1;rquez</surname><given-names>C</given-names></name><name><surname>Us&#x000f3;n</surname><given-names>M</given-names></name><name><surname>Hankiewicz</surname><given-names>K</given-names></name><name><surname>Gallardo</surname><given-names>E</given-names></name><name><surname>Illa</surname><given-names>I</given-names></name></person-group><article-title>Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies</article-title><source>Neurology</source><year>2010</year><volume>75</volume><issue>4</issue><fpage>316</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181ea1564</pub-id><pub-id pub-id-type="pmid">20574037</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Paradas C, Llauger J, Diaz-Manera J, Rojas-Garc&#x000ed;a R, De Luna N, Iturriaga C, M&#x000e1;rquez C, Us&#x000f3;n M, Hankiewicz K, Gallardo E, Illa I (2010) Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology 75(4):316&#x02013;323. 10.1212/WNL.0b013e3181ea1564. (<bold>Epub 2010 Jun 23</bold>)<pub-id pub-id-type="pmid">20574037</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>D</given-names></name><name><surname>Morrow</surname><given-names>J</given-names></name><name><surname>Alonso-P&#x000e9;rez</surname><given-names>J</given-names></name><name><surname>Reyes</surname><given-names>D</given-names></name><name><surname>Carbayo</surname><given-names>A</given-names></name><name><surname>Bisogni</surname><given-names>G</given-names></name><name><surname>Cateruccia</surname><given-names>M</given-names></name><name><surname>Monforte</surname><given-names>M</given-names></name><name><surname>Tasca</surname><given-names>G</given-names></name><name><surname>Alangary</surname><given-names>A</given-names></name><name><surname>Marini-Bettolo</surname><given-names>C</given-names></name><name><surname>Sabatelli</surname><given-names>M</given-names></name><name><surname>Laura</surname><given-names>M</given-names></name><name><surname>Ramdharry</surname><given-names>G</given-names></name><name><surname>Bola&#x000f1;o-D&#x000ed;az</surname><given-names>C</given-names></name><name><surname>Turon-Sans</surname><given-names>J</given-names></name><name><surname>T&#x000f6;pf</surname><given-names>A</given-names></name><name><surname>Guglieri</surname><given-names>M</given-names></name><name><surname>Rossor</surname><given-names>AM</given-names></name><name><surname>Olive</surname><given-names>M</given-names></name><name><surname>Bertini</surname><given-names>E</given-names></name><name><surname>Straub</surname><given-names>V</given-names></name><name><surname>Reilly</surname><given-names>MM</given-names></name><name><surname>Rojas-Garc&#x000ed;a</surname><given-names>R</given-names></name><name><surname>D&#x000ed;az-Manera</surname><given-names>J</given-names></name></person-group><article-title>Muscle magnetic resonance imaging of a large cohort of distal hereditary motor neuropathies reveals characteristic features useful for diagnosis</article-title><source>Neuromuscul Disord</source><year>2023</year><volume>33</volume><issue>10</issue><fpage>744</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2023.08.010</pub-id><pub-id pub-id-type="pmid">37704504</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Esteller D, Morrow J, Alonso-P&#x000e9;rez J, Reyes D, Carbayo A, Bisogni G, Cateruccia M, Monforte M, Tasca G, Alangary A, Marini-Bettolo C, Sabatelli M, Laura M, Ramdharry G, Bola&#x000f1;o-D&#x000ed;az C, Turon-Sans J, T&#x000f6;pf A, Guglieri M, Rossor AM, Olive M, Bertini E, Straub V, Reilly MM, Rojas-Garc&#x000ed;a R, D&#x000ed;az-Manera J (2023) Muscle magnetic resonance imaging of a large cohort of distal hereditary motor neuropathies reveals characteristic features useful for diagnosis. Neuromuscul Disord 33(10):744&#x02013;753. 10.1016/j.nmd.2023.08.010. (<bold>Epub 2023 Aug 28</bold>)<pub-id pub-id-type="pmid">37704504</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Gallien</surname><given-names>S</given-names></name><name><surname>Mahr</surname><given-names>A</given-names></name><name><surname>R&#x000e9;ty</surname><given-names>F</given-names></name><name><surname>Kambouchner</surname><given-names>M</given-names></name><name><surname>Lhote</surname><given-names>F</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Guillevin</surname><given-names>L</given-names></name></person-group><article-title>Magnetic resonance imaging of skeletal muscle involvement in limb restricted vasculitis</article-title><source>Ann Rheum Dis</source><year>2002</year><volume>61</volume><issue>12</issue><fpage>1107</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1136/ard.61.12.1107</pub-id><pub-id pub-id-type="pmid">12429545</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Gallien S, Mahr A, R&#x000e9;ty F, Kambouchner M, Lhote F, Cohen P, Guillevin L (2002) Magnetic resonance imaging of skeletal muscle involvement in limb restricted vasculitis. Ann Rheum Dis 61(12):1107&#x02013;1109. 10.1136/ard.61.12.1107<pub-id pub-id-type="pmid">12429545</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Tasca</surname><given-names>G</given-names></name><name><surname>Iannaccone</surname><given-names>E</given-names></name><name><surname>Monforte</surname><given-names>M</given-names></name><etal/></person-group><article-title>Muscle MRI in Becker muscular dystrophy</article-title><source>Neuromuscul Disord</source><year>2012</year><volume>22</volume><issue>Suppl 2</issue><fpage>S100</fpage><lpage>S106</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2012.05.015</pub-id><pub-id pub-id-type="pmid">22980760</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Tasca G, Iannaccone E, Monforte M et al (2012) Muscle MRI in Becker muscular dystrophy. Neuromuscul Disord 22(Suppl 2):S100&#x02013;S106<pub-id pub-id-type="pmid">22980760</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Chino</surname><given-names>N</given-names></name><name><surname>Ishihara</surname><given-names>T</given-names></name><etal/></person-group><article-title>Muscle damage progression in Duchenne muscular dystrophy evaluated by a new quantitative computed tomography method</article-title><source>Arch Phys Med Rehabil</source><year>1993</year><volume>74</volume><fpage>507</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1016/0003-9993(93)90115-Q</pub-id><pub-id pub-id-type="pmid">8489361</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Liu M, Chino N, Ishihara T et al (1993) Muscle damage progression in Duchenne muscular dystrophy evaluated by a new quantitative computed tomography method. Arch Phys Med Rehabil 74:507&#x02013;514<pub-id pub-id-type="pmid">8489361</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Oliwa</surname><given-names>A</given-names></name><name><surname>Hocking</surname><given-names>C</given-names></name><name><surname>Hamilton</surname><given-names>MJ</given-names></name><name><surname>McLean</surname><given-names>J</given-names></name><name><surname>Cumming</surname><given-names>S</given-names></name><name><surname>Ballantyne</surname><given-names>B</given-names></name><name><surname>Jampana</surname><given-names>R</given-names></name><name><surname>Longman</surname><given-names>C</given-names></name><name><surname>Monckton</surname><given-names>DG</given-names></name><name><surname>Farrugia</surname><given-names>ME</given-names></name><collab>Scottish Myotonic Dystrophy Consortium</collab></person-group><article-title>Masseter muscle volume as a disease marker in adult-onset myotonic dystrophy type 1</article-title><source>Neuromuscul Disord</source><year>2022</year><volume>32</volume><issue>11&#x02013;12</issue><fpage>893</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2022.09.005</pub-id><pub-id pub-id-type="pmid">36207221</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Oliwa A, Hocking C, Hamilton MJ, McLean J, Cumming S, Ballantyne B, Jampana R, Longman C, Monckton DG, Farrugia ME, Scottish Myotonic Dystrophy Consortium (2022) Masseter muscle volume as a disease marker in adult-onset myotonic dystrophy type 1. Neuromuscul Disord 32(11&#x02013;12):893&#x02013;902. 10.1016/j.nmd.2022.09.005. (<bold>Epub 2022 Sep 24</bold>)<pub-id pub-id-type="pmid">36207221</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Solbakken</surname><given-names>G</given-names></name><name><surname>Bj&#x000f8;rnar&#x000e5;</surname><given-names>B</given-names></name><name><surname>Kirkhus</surname><given-names>E</given-names></name><name><surname>Nguyen</surname><given-names>B</given-names></name><name><surname>Hansen</surname><given-names>G</given-names></name><name><surname>Frich</surname><given-names>JC</given-names></name><name><surname>&#x000d8;rstavik</surname><given-names>K</given-names></name></person-group><article-title>MRI of trunk muscles and motor and respiratory function in patients with myotonic dystrophy type 1</article-title><source>BMC Neurol</source><year>2019</year><volume>19</volume><issue>1</issue><fpage>135</fpage><pub-id pub-id-type="doi">10.1186/s12883-019-1357-8</pub-id><pub-id pub-id-type="pmid">31216995</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Solbakken G, Bj&#x000f8;rnar&#x000e5; B, Kirkhus E, Nguyen B, Hansen G, Frich JC, &#x000d8;rstavik K (2019) MRI of trunk muscles and motor and respiratory function in patients with myotonic dystrophy type 1. BMC Neurol 19(1):135. 10.1186/s12883-019-1357-8<pub-id pub-id-type="pmid">31216995</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Rijken</surname><given-names>NH</given-names></name><name><surname>van Engelen</surname><given-names>BG</given-names></name><name><surname>de Rooy</surname><given-names>JW</given-names></name><name><surname>Geurts</surname><given-names>AC</given-names></name><name><surname>Weerdesteyn</surname><given-names>V</given-names></name></person-group><article-title>Trunk muscle involvement is most critical for the loss of balance control in patients with facioscapulohumeral muscular dystrophy</article-title><source>Clin Biomech (Bristol, Avon)</source><year>2014</year><volume>29</volume><issue>8</issue><fpage>855</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiomech.2014.07.008</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Rijken NH, van Engelen BG, de Rooy JW, Geurts AC, Weerdesteyn V (2014) Trunk muscle involvement is most critical for the loss of balance control in patients with facioscapulohumeral muscular dystrophy. Clin Biomech (Bristol, Avon) 29(8):855&#x02013;860. 10.1016/j.clinbiomech.2014.07.008. (<bold>Epub 2014 Aug 10</bold>)</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Sugie</surname><given-names>K</given-names></name><name><surname>Sugie</surname><given-names>M</given-names></name><name><surname>Taoka</surname><given-names>T</given-names></name><name><surname>Tonomura</surname><given-names>Y</given-names></name><name><surname>Kumazawa</surname><given-names>A</given-names></name><name><surname>Izumi</surname><given-names>T</given-names></name><name><surname>Kichikawa</surname><given-names>K</given-names></name><name><surname>Ueno</surname><given-names>S</given-names></name></person-group><article-title>Characteristic MRI findings of upper limb muscle involvement in myotonic dystrophy type 1</article-title><source>PLoS&#x000a0;One</source><year>2015</year><volume>10</volume><issue>4</issue><fpage>e0125051</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0125051</pub-id><pub-id pub-id-type="pmid">25919300</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Sugie K, Sugie M, Taoka T, Tonomura Y, Kumazawa A, Izumi T, Kichikawa K, Ueno S (2015) Characteristic MRI findings of upper limb muscle involvement in myotonic dystrophy type 1. PLoS&#x000a0;One 10(4):e0125051. 10.1371/journal.pone.0125051<pub-id pub-id-type="pmid">25919300</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Shin</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name></person-group><article-title>Lower limb muscle magnetic resonance imaging in myotonic dystrophy type 1 correlates with the six-minute walk test and CTG repeats</article-title><source>Neuromuscul Disord</source><year>2018</year><volume>28</volume><issue>1</issue><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2017.08.005</pub-id><pub-id pub-id-type="pmid">29066035</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Park D, Lee SH, Shin JH, Park JS (2018) Lower limb muscle magnetic resonance imaging in myotonic dystrophy type 1 correlates with the six-minute walk test and CTG repeats. Neuromuscul Disord 28(1):29&#x02013;37. 10.1016/j.nmd.2017.08.005. (<bold>Epub 2017 Aug 24</bold>)<pub-id pub-id-type="pmid">29066035</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>